Sean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) Stock

Amgen, Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Amgen, Inc. (NASDAQ:AMGN) traded up $2.47 during midday trading on Wednesday, hitting $188.01. 4,009,525 shares of the company’s stock traded hands, compared to its average volume of 2,700,000. The stock has a market cap of $136,480.00, a price-to-earnings ratio of 16.98, a P/E/G ratio of 2.70 and a beta of 1.36. Amgen, Inc. has a 52 week low of $150.38 and a 52 week high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business’s revenue was down .7% on a year-over-year basis. During the same period in the previous year, the firm earned $3.02 EPS. equities research analysts forecast that Amgen, Inc. will post 12.71 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s payout ratio is presently 41.55%.

Amgen announced that its Board of Directors has approved a stock repurchase program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Hedge funds and other institutional investors have recently modified their holdings of the business. Baker Ellis Asset Management LLC purchased a new stake in shares of Amgen in the 3rd quarter worth about $108,000. Jackson Grant Investment Advisers Inc. boosted its position in shares of Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares in the last quarter. Phocas Financial Corp. purchased a new stake in shares of Amgen in the 2nd quarter worth about $110,000. Omnia Family Wealth LLC boosted its position in shares of Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after buying an additional 147 shares in the last quarter. Finally, Grove Bank & Trust boosted its position in shares of Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after buying an additional 341 shares in the last quarter. Institutional investors own 78.48% of the company’s stock.

Several equities analysts have issued reports on the stock. Credit Suisse Group reissued a “neutral” rating and issued a $186.00 price objective (up from $177.00) on shares of Amgen in a research note on Friday, September 29th. Royal Bank of Canada dropped their price objective on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a research note on Thursday, October 26th. Oppenheimer set a $205.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Friday, January 5th. Morgan Stanley dropped their price objective on shares of Amgen from $196.00 to $193.00 and set an “overweight” rating on the stock in a research note on Thursday, October 26th. Finally, Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective on the stock in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $190.15.

TRADEMARK VIOLATION WARNING: “Sean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) Stock” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/17/sean-e-harper-sells-1525-shares-of-amgen-inc-amgn-stock.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply